<DOC>
	<DOCNO>NCT00359385</DOCNO>
	<brief_summary>We investigate whether , surgical cure primary hyperparathyroidism , alendronate provide even great beneficial skeletal effect parathyroidectomy alone . Primary Hyperparathyroidism ( PHPT ) disorder associate bone loss . After successful surgery PHPT bone density improve without treatment . However , possible bone density might improve even great extent Fosamax use surgical cure . Fosamax approve FDA prevention treatment osteoporosis , goal project determine whether successful surgical cure PHPT , Fosamax even well skeleton parathyroid surgery alone .</brief_summary>
	<brief_title>The Effects Alendronate After Cure Primary Hyperparathyroidism</brief_title>
	<detailed_description>Study Purpose : Hypothesis : After successful surgical cure primary hyperparathyroidism alendronate provide even great beneficial skeletal effect parathyroidectomy alone . Primary hyperparathyroidism ( PHPT ) typically disorder mild hypercalcemia . Skeletal involvement demonstrate bone densitometry perform . Effects excess PTH bone include preferential involvement cortical bone ( e.g . forearm ) relative spar cancellous bone ( e.g . vertebral spine ) . Bone property , bone turnover , size geometry , also alter PHPT . The cure PHPT removal abnormal parathyroid tissue . In absence medical intervention , bone mass increase briskly successful surgical treatment PHPT . Parathyroid surgery also promptly reduce bone remodeling , typically increase PHPT , normal value . Bone resorption marker fall first , follow bone formation marker . The difference time course rapid fall resorption marker gradual fall formation marker provide window time bone mass increase rapidly . The post-surgical increase BMD attribute filling-in , mineralization , enlarge , PTH-driven , remodel space . Whether gain bone density could achieve prompt great suppression bone resorption postoperative period unknown . The potent bisphosphonate , alendronate ( Fosamax ) , reduce bone remodel enhances secondary mineralization . It show increase bone density subject PHPT undergo parathyroid surgery . The goal project test hypothesis successful surgical cure PHPT , alendronate provide even great beneficial skeletal effect parathyroidectomy alone . Study Design Statistical Analysis : The clinical investigation primary outcome variable increase lumbar spine density ( DXA ) alendronate use first year surgery . The patient stratify BMD upon presentation , show variable response parathyroidectomy depend initial spine BMD . The study design randomize , double-blind , placebo , 1-year , control clinical trial , patient receive alendronate 70 mg weekly placebo tablet identical appearance . As secondary endpoint , also plan examine effect alendronate parathyroidectomy bone structure skeletal dynamic use sensitive , state-of-the-art , non-invasive quantitative tool . With central peripheral quantitative compute tomography , investigate change bone size , geometry cortical porosity cancellous cortical bone . With serum urinary marker bone turnover , determine whether alendronate hastens control bone resorption , thus enhance discordance bone formation resorption lead even great improvement bone mineral density . There 3 Specific Aims ; measurable successful parathyroid surgery : Specific Aim # 1 investigate effect alendronate bone mineral density . Specific Aim # 2 determine whether alendronate alters bone turnover maximize augment window define rapid fall bone resorption slow fall bone formation . Specific Aim # 3 characterize effect alendronate bone size bone geometry cancellous cortical skeletal compartment use QCT pQCT In Specific Aim # 1 obtain data primary outcome . This include data regard change lumbar spine , well hip distal 1/3 radius . The rate change BMD sit also determine BMD measurement within 1-year period observation . Specific Aim # 2 examine potential mechanism great improvement bone density , namely change bone turnover dynamic would favor great accumulation bone mineral alendronate therapy . With Specific Aim # 3 obtain detailed information change bone structure likely occur sophisticated tool DXA . This allow specific assessment change cancellous vs. cortical bone bone size , geometry porosity . Two group 20 patient self-administer weekly oral pill , alendronate placebo , 12 month . This number give u statistical power make observation plan . 18 subject per group ( n=36 ) allow detection group difference 0.059 gm/cm2 lumbar spine BMD one year , power 80 % , use t-test two-tailed alpha 0.05 . Calculation base preliminary data bone density improve 0.053 Â± 0.061 gm/cm2 ( 6.7 % change ) without intervention surgery . We able detect overall change treatment group 0.053 + .059 = .112 gm/cm2 , 14 % surgery . We recruit additional 4 subject ( 36+ 4 = 40 ) account drop-outs . When main publication publish , within two year completion data collection , prepare data share file comprises follow component accompany annotation : protocol , procedure manual , operation manual , blank copy report form use study , schedule assessment , data dictionary provide data storage specification field , study database table represent capture audited data ; final data analytic data table list program statement responsible data recode sub-setting , data summary data table include descriptive statistic validation value integrity , write description study conduct noteworthy detail anticipate potentially affect data interpretation . Study visit Procedures : Certain test perform part accept procedure patient PHPT , obtain specifically research purpose . There total 6 visit study : The pre-parathyroidectomy baseline/safety visit ( `` -1Month '' visit ) occur approximately one month prior parathyroidectomy , post-parathyroidectomy baseline ( `` Zero visit '' ) begin study drug . There also one-month ( `` M1 '' ) , three-month ( `` M3 '' ) , six-month ( `` M6 '' ) , twelve-month visit ( `` 12M '' ) . The `` -1Month '' visit : At visit , potential participant screen study . That , consent obtain , inclusion exclusion criterion satisfy , baseline value obtain . The test perform visit divide two category : research safety . Research Testing include DXA , QCT , pQCT well serum urinary index bone mineral metabolism ( serum Calcium , PO4 , Albumin , PTH , Vitamin D , P1NP , BSAP , urinary NTX DPD ) . This reflect standard baseline information capture prior parathyroidectomy clinical setting , include serum calcium , vitamin D , PTH well bone mineral density DXA . Safety Testing include lab test perform satisfy inclusion exclusion criterion . From participant pre-surgical test parathyroidectomy ( always include CBC , BMET , PT , PTT ) able obtain baseline safety data . Other baseline safety test obtain serum BUN , Creatinine , AST ALT . The complete list result seek `` -1Month '' visit : Serum BUN , Creatinine , AST , ALT , Calcium , PTH , Vitamin D , PO4 , Albumin , P1NP , BSAP urinary NTX DPD , well bone mineral density DXA , QCT , pQCT . The `` ZERO '' visit : In order determine parathyroidectomy successful person surgery routinely serum Calcium PTH perform . The result serum Calcium particular immediately reflect success surgery . Therefore , final screening criterion , participant provide u result routine post-parathyroidectomy serum Calcium ( PTH , later time ) . Study drug initiate long one month parathyroidectomy , since change mineral metabolism likely start immediately surgery . At visit obtain serum Calcium PTH research purpose . We also randomize participant visit receive either alendronate placebo alendronate . We provide participant study pill take first day follow ZERO visit . The complete list thing do `` ZERO visit '' : Serum Calcium PTH MONTH 1 visit : Serum urinary index bone mineral metabolism ( serum Calcium , PO4 , Albumin , PTH , Vitamin D , P1NP , BSAP , urinary NTX DPD ) collect . MONTH 3 visit : Serum urinary index bone mineral metabolism ( serum Calcium , PO4 , Albumin , PTH , Vitamin D , P1NP , BSAP , urinary NTX DPD ) collect . MONTH 6 visit : Serum urinary index bone mineral metabolism ( serum Calcium , PO4 , Albumin , PTH , Vitamin D , P1NP , BSAP , urinary NTX DPD ) collect DXA perform . Also , participant supply study pill . MONTH 12 visit : Serum BUN , Creatinine , AST , ALT , Calcium , PTH , Vitamin D , PO4 , Albumin , P1NP , BSAP urinary NTX DPD , well bone mineral density DXA , QCT , pQCT perform visit . Study Drugs : Alendronate , study drug , show safe many large , randomized , placebo-controlled trial individual osteoporosis FDA- approve prevention treatment osteoporosis . It also show safe individual PHPT . In clinical practice , common side effect alendronate gastrointestinal discomfort ( information see RISKS ) . Study patient instruct administer alendronate ( placebo ) minimize likelihood side effect . Medical Devices : Dual x-ray absorptometry ( DXA ) , XtremeCT ( pQCT ) , QCT ( cQCT )</detailed_description>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>patient PHPT negative Tscore BMD lumbar spine surgery ; successful surgery PHPT document normalization serum calcium PTH level within 1 week study initiation . vitamin D deficiency ; concomitant disease might affect mineral metabolism hyperthyroidism , Paget 's disease bone , diabetes mellitus , chronic liver renal disease , acromegaly , Cushing 's syndrome , rheumatoid arthritis , myeloma ; woman within 5 year menopause ; gastrointestinal disorder , surgery drug affect absorption ; treatment bisphosphonate within 2 year parathyroidectomy ; treatment follow medication recently 6 month prior enrollment : estrogen , progestin , raloxifene , calcitonin , systemic corticosteroid , fluoride , lithium , loop diuretic , methotrexate ; abnormality esophagus delay esophageal empty stricture achalasia ; inability stand sit upright least 30 minute ; increase risk aspiration ; hypersensitivity alendronate ; hypocalcemia ; pregnancy nursing ; ( woman within childbearing year advise conceive study ) ; age &lt; 18 year old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>primary hyperparathyroidism</keyword>
	<keyword>hyperparathyroidism</keyword>
	<keyword>PHPT</keyword>
	<keyword>PTH</keyword>
	<keyword>hypercalcemia</keyword>
	<keyword>bone density</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone turnover</keyword>
	<keyword>DXA</keyword>
	<keyword>pQCT</keyword>
	<keyword>cQCT</keyword>
	<keyword>alendronate</keyword>
	<keyword>Fosamax</keyword>
	<keyword>parathyroid hormone</keyword>
	<keyword>parathyroid surgery</keyword>
	<keyword>parathyroidectomy</keyword>
	<keyword>Silverberg</keyword>
	<keyword>Rubin</keyword>
	<keyword>Bilezikian</keyword>
	<keyword>treatment</keyword>
</DOC>